Rashmi Ramesh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rashmi Ramesh has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Shubha Gopal
Department of Studies in Microbiology, Manasagangotri, University of Mysore, Mysuru, India
3 shared publications - Aditya Chandrashekar
Internal Medicine, Bangalore Medical College and Research Institute, Bangalore, India
1 shared publication - Akshay Ravish
Laboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Mysore 570006, Karnataka, India
1 shared publication - Alexey Yu. Sukhorukov
Laboratory of organic and metal-organic nitrogen-oxygen systems (LOMONOS, N. D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky prospect, 47, Moscow, Russian Federation
1 shared publication - Arunkumar Mohan
Laboratory of Chemical Biology, Department of Studies in Organic Chemistry, University of Mysore, Mysore 570006, Karnataka, India
1 shared publication - Babu Shubha Priya
Department of Studies in Chemistry, University of Mysore
1 shared publication
Latest Publications
- 14 March 2026
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 42 (3) , 138
In vitro antibacterial activity and in silico validation of phytocompound Emodin from Rheum Emodi Wall. Ex Meissn. against Staphylococcus aureus and Enterobacter cloacae
Antimicrobial resistance continues to outpace the development of new antibiotics, creating an urgent need for alternative antibacterial agents. We evaluated Emodin, a plant-derived phytocompound, for antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant (MDR) Enterobacter cloacae. Emodin demonstrated inhibitory activity against both organisms with a minimum inhibitory concentration (MIC) of 0.156 mg/mL and bactericidal activity at higher concentrations, with minimum bactericidal concentrations (MBCs) of 1.25 mg/mL for MRSA and 2.5 mg/mL for MDR E. cloacae. In growth-curve experiments, Emodin produced sustained, time-dependent suppression of bacterial growth relative to untreated controls. Stability testing showed preserved antibacterial activity at 4 °C to 50 °C, reduced activity at 80 °C to 100 °C, and reduced activity under acidic conditions, with relative stability at neutral to alkaline pH. Mechanistic studies consistently supported membrane-targeting effects, including increased release of nucleic acids and cytoplasmic proteins, marked ultrastructural damage on scanning electron microscopy (SEM), and enhanced propidium iodide (PI) uptake, indicating compromised membrane integrity. In silico docking suggested favorable binding of Emodin to S. aureus Sortase A (− 7.4 kcal/mol) and the E. cloacae LptBFGC complex (− 6.4 kcal/mol). SwissADME profiling further supported drug-likeness, with high predicted gastrointestinal absorption and no Lipinski rule-of-five violations. Collectively, these findings position Emodin as a promising phytocompound and a strong candidate for the development of plant-based therapeutics targeting MDR pathogens, warranting further validation across a broader range of resistant clinical isolates and in vivo safety and efficacy profiling. Graphical Abstract
- 14 March 2026
- Published by Springer Nature in World Journal of Microbiology and Biotechnology
- Vol. 42 (3) , 138
In vitro antibacterial activity and in silico validation of phytocompound Emodin from Rheum Emodi Wall. Ex Meissn. against Staphylococcus aureus and Enterobacter cloacae
Antimicrobial resistance continues to outpace the development of new antibiotics, creating an urgent need for alternative antibacterial agents. We evaluated Emodin, a plant-derived phytocompound, for antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and multidrug-resistant (MDR) Enterobacter cloacae. Emodin demonstrated inhibitory activity against both organisms with a minimum inhibitory concentration (MIC) of 0.156 mg/mL and bactericidal activity at higher concentrations, with minimum bactericidal concentrations (MBCs) of 1.25 mg/mL for MRSA and 2.5 mg/mL for MDR E. cloacae. In growth-curve experiments, Emodin produced sustained, time-dependent suppression of bacterial growth relative to untreated controls. Stability testing showed preserved antibacterial activity at 4 °C to 50 °C, reduced activity at 80 °C to 100 °C, and reduced activity under acidic conditions, with relative stability at neutral to alkaline pH. Mechanistic studies consistently supported membrane-targeting effects, including increased release of nucleic acids and cytoplasmic proteins, marked ultrastructural damage on scanning electron microscopy (SEM), and enhanced propidium iodide (PI) uptake, indicating compromised membrane integrity. In silico docking suggested favorable binding of Emodin to S. aureus Sortase A (− 7.4 kcal/mol) and the E. cloacae LptBFGC complex (− 6.4 kcal/mol). SwissADME profiling further supported drug-likeness, with high predicted gastrointestinal absorption and no Lipinski rule-of-five violations. Collectively, these findings position Emodin as a promising phytocompound and a strong candidate for the development of plant-based therapeutics targeting MDR pathogens, warranting further validation across a broader range of resistant clinical isolates and in vivo safety and efficacy profiling. Graphical Abstract
- 10 May 2025
- Published by Springer Nature in Archives of Microbiology
- Vol. 207 (6) , 1-21
Pseudomonas aeruginosa biofilm: treatment strategies to combat infection
Pseudomonas aeruginosa is an opportunistic human pathogenic bacterium that is a common cause of both acute and chronic infections. Multidrug-resistant P. aeruginosa poses a significant challenge to antibiotics and therapeutic approaches due to its pathogenicity, virulence, and biofilm-forming ability mediated by quorum sensing. Understanding the pathogenic mechanisms is essential for developing potential drug targets. In this regard, strategies aimed at combating the targeted inhibition of virulence, quorum sensing pathways, secretion systems, biofilm-associated two-component systems, and signalling system regulators (such as c-di-GMP) associated with biofilm formation are critical. Several new antimicrobial agents have been developed using these strategies, including antimicrobial peptides, bacteriophages, nanoantibiotics, photodynamics, and natural products, which are considered promising therapeutic tools. In this review, we address the concept of biofilms, their regulation, and recent treatment strategies to target P. aeruginosa, a clinically significant pathogen known for biofilm formation.
- 10 May 2025
- Published by Springer Nature in Archives of Microbiology
- Vol. 207 (6) , 1-21
Pseudomonas aeruginosa biofilm: treatment strategies to combat infection
Pseudomonas aeruginosa is an opportunistic human pathogenic bacterium that is a common cause of both acute and chronic infections. Multidrug-resistant P. aeruginosa poses a significant challenge to antibiotics and therapeutic approaches due to its pathogenicity, virulence, and biofilm-forming ability mediated by quorum sensing. Understanding the pathogenic mechanisms is essential for developing potential drug targets. In this regard, strategies aimed at combating the targeted inhibition of virulence, quorum sensing pathways, secretion systems, biofilm-associated two-component systems, and signalling system regulators (such as c-di-GMP) associated with biofilm formation are critical. Several new antimicrobial agents have been developed using these strategies, including antimicrobial peptides, bacteriophages, nanoantibiotics, photodynamics, and natural products, which are considered promising therapeutic tools. In this review, we address the concept of biofilms, their regulation, and recent treatment strategies to target P. aeruginosa, a clinically significant pathogen known for biofilm formation.
- Open Access
- 17 October 2023
- Published by MDPI AG in Applied Microbiology
- Vol. 3 (4) , 1214-1228
Development of Novel Indole and Coumarin Derivatives as Antibacterial Agents That Target Histidine Kinase in S. aureus
Heterocyclic compounds can specifically regulate bacterial development by targeting specific bacterial enzymes and metabolic pathways. The ESKAPE pathogens are multidrug-resistant and cause nosocomial infections, which is one of the greatest challenges in clinical practice. The search for novel agents to combat resistant bacteria has become one of the most important areas of antibacterial research today. Heterocyclic compounds offer a valuable strategy in the fight against resistance as they can be designed to interact with bacterial targets that are less prone to developing resistance mechanisms. Bacterial histidine kinases (HKs), which are a component of two-component bacterial systems, are a promising target for new antibacterial compounds. We have designed and synthesized novel indole derivatives as antibacterial agents. Among the series, indole-coumarin (4b) and bisindole (4e) have shown the best inhibitory activity against S. aureus. Further, in silico docking studies show that compounds 4b and 4e could target histidine kinases in bacteria.
- 17 October 2023
- Published by MDPI AG in Applied Microbiology
- Vol. 3 (4) , 1214-1228
Open AccessDevelopment of Novel Indole and Coumarin Derivatives as Antibacterial Agents That Target Histidine Kinase in S. aureus
Heterocyclic compounds can specifically regulate bacterial development by targeting specific bacterial enzymes and metabolic pathways. The ESKAPE pathogens are multidrug-resistant and cause nosocomial infections, which is one of the greatest challenges in clinical practice. The search for novel agents to combat resistant bacteria has become one of the most important areas of antibacterial research today. Heterocyclic compounds offer a valuable strategy in the fight against resistance as they can be designed to interact with bacterial targets that are less prone to developing resistance mechanisms. Bacterial histidine kinases (HKs), which are a component of two-component bacterial systems, are a promising target for new antibacterial compounds. We have designed and synthesized novel indole derivatives as antibacterial agents. Among the series, indole-coumarin (4b) and bisindole (4e) have shown the best inhibitory activity against S. aureus. Further, in silico docking studies show that compounds 4b and 4e could target histidine kinases in bacteria.